Hematology
From the Journals
Extended half-life clotting factors cut infusions, hike prices
The use of extended half-life clotting factors was able to significantly reduce the number of infusions but the cost went up significantly.
From the Journals
HAVEN 4: Monthly emicizumab shows value
Emicizumab was effective as a monthly treatment for patients with hemophilia A, both with and without inhibitors, according to an ongoing phase 3...
Conference Coverage
Study highlights lack of data on transgender leukemia patients
NEWPORT BEACH, CALIF. – Researchers identified transgender leukemia patients by detecting gender-karyotype mismatches.
Photo Rounds
Rash with hair loss
Commentary
Powerful breast-implant testimony constrained by limited evidence
SILVER SPRING, MD. – Women report personal horror stories of apparent breast-implant complications, but systematically-collected data remain...
Conference Coverage
FDA panel leans toward more robust breast implant surveillance
SILVER SPRING, MD. – Amid concern over two breast implant complications – anaplastic large cell lymphoma and autoimmune symptoms – an FDA panel...
Video
AUGUSTUS: Dual surpasses triple therapy when AFib patients have PCI or ACS
NEW ORLEANS – Dropping aspirin but keeping anticoagulation with apixaban and antiplatelet clopidogrel was effective and associated with less...
Conference Coverage
Andexanet alfa effectively reverses factor Xa inhibition
HONOLULU – The drug establishes good or excellent hemostasis in 82% of patients with acute major bleeding associated...
Conference Coverage
Repeat VTE risk heightened in HIV patients
SEATTLE – Two studies detail the risk factors of first-time venous thromboembolism and heightened incidence of repeat VTE in patients with HIV.
Conference Coverage
Novel transplant regimen improves survival in primary immunodeficiency
HOUSTON – Allo-HCT following a novel reduced-intensity conditioning regimen was largely successful in an NIH study of adults and children with...
Conference Coverage
Gene therapy in hemophilia is just version 1.0
PRAGUE – The biggest question for gene therapy today is durability, according to Dr. John Pasi.